Montserrat C. S.
- Country
- Spain
- Department
- Hematología
Research Overview
- Phase III Randomized Trial of Bortezomib, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Carfilzomib, and Daratumumab in Elderly Patients with Newly Diagnosed Multiple Myeloma
- Phase III Trial Comparing Extended Lenalidomide-Bortezomib-Dexamethasone with Early Rescue vs. Isatuximab-Lenalidomide-Bortezomib-Dexamethasone vs. Isatuximab-Lenalidomide-Iberdomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Candidates for Autologous Stem Cell Transplantation
Data & Insights
Has run more than one trial at 39 of 55 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of newly-diagnosed multiple myeloma (NDMM), focusing on innovative therapeutic approaches for patients eligible for stem cell transplantation.
- Multiple Myeloma Treatment
- Autologous Stem Cell Transplantation
- Novel Drug Combinations
Their research encompasses the evaluation of combination therapies including proteasome inhibitors and immunomodulatory drugs.
Immunotherapy Research
The investigator explores monoclonal antibody therapy in blood cancers, with particular attention to isatuximab-based regimens for myeloma treatment.
- Targeted Antibody Therapy
- Combination Immunotherapy
- Treatment Response Assessment
Their work includes evaluation of minimal residual disease (MRD) monitoring using advanced flow cytometry techniques.
Treatment Optimization
The investigator studies optimized treatment sequences incorporating induction therapy, consolidation, and maintenance approaches for myeloma patients.
- Treatment Sequencing
- Response-Adapted Therapy
- Long-term Disease Control
Their research includes investigation of early rescue intervention strategies in treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.